Open access
Oct 2026
AI-based prognosis and chemotherapy benefit in node-positive, HR+ breast cancer: a blinded external validation on SWOG-8814 trial
Background The benefit from adjuvant chemotherapy varies among patients with postmenopausal, node-positive, hormone receptor-positive breast cancer. Genomic assays identify patients likely to benefit from chemotherapy but are expensive and tissue consuming. AI-enabled biomarkers may provide scalable alternatives. We pe...
A. Thompson, A. Meisner, K. Albain et al.
· medRxiv · 0 citations